FEMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Femasys Inc (FEMY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company's innovative product has potential in a large market, the technical indicators are bearish, financial performance shows declining profitability, and there are no recent positive trading trends or news catalysts. It is better to wait for clearer signs of growth or improved sentiment before investing.
The technical indicators are bearish. The MACD is negatively expanding below 0, the RSI is neutral at 28.095, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 0.506, with resistance at 0.612. Overall, the trend suggests weakness in the stock.
The company has an innovative product, FemBloc, targeting a multi-billion-dollar market. It has CE Mark clearance and is undergoing FDA registration trials, which could drive future growth if successful.
The stock has bearish technical indicators, declining financial performance with a significant drop in net income (-22.45% YoY) and EPS (-58.33% YoY), and no recent news or trading trends to support positive sentiment. Additionally, hedge funds and insiders are neutral, and there is no recent congress trading data.
In Q3 2025, revenue increased by 31.44% YoY to $729,394, but net income dropped by 22.45% YoY to -$4,194,821. EPS declined significantly by 58.33% YoY to -0.1, and gross margin fell by 7.50% YoY to 47.97%. This indicates growth in revenue but worsening profitability.
Lake Street analyst Ben Haynor initiated coverage with a Buy rating and a $1.50 price target, citing the potential of FemBloc in a large market. However, no other recent analyst updates or price target changes are available.
